Testosterone for women
Testosterone for women: why symptoms and blood levels do not diagnose “low T,” where evidence supports therapy, and how careful evaluation and monitoring work.
Start here
Symptoms, levels & HSDD
- Testosterone Cypionate for Women: What to KnowTestosterone cypionate is an injectable product labeled for male hypogonadism, not a standard first-line menopause treatment for women. For women after menopause, the strongest evidence-backed testosterone use is carefully diagnosed hypoactive sexual desire disorder with physiologic female-range dosing and monitoring. A 2019 meta-analysis included 36 randomized trials with 8,480 women, but it does not create a generic injection-dose protocol. Injections can make dose overshoot harder to manage, so the key question is whether testosterone is appropriate at all, whether other causes of low desire were reviewed, and how exposure will stay out of male-range territory. [1]
- How Quickly Does Testosterone Therapy Work?For women after menopause using testosterone for carefully assessed hypoactive sexual desire disorder, the honest timeline is weeks to months, not days. International Society for the Study of Women's Sexual Health says average efficacy emerges about 6 to 8 weeks after starting therapy, many women feel improvement after 4 weeks, maximal effects in sexual desire and satisfactory sexual events occur around 12 weeks, and therapy should not continue beyond 6 months without clinically meaningful improvement. [1] This timeline does not support using testosterone as a fast treatment for fatigue, weight, mood, muscle, cognition, or anti-aging. [2] [5]
- Testosterone and Vaginal Dryness After MenopauseTestosterone should not be framed as a primary vaginal-dryness treatment after menopause. The 2025 AUA/SUFU/AUGS genitourinary syndrome of menopause guideline says clinicians diagnose genitourinary syndrome of menopause based on symptoms, with or without exam findings, after ruling out other causes, and that low-dose vaginal estrogen has the most robust genitourinary syndrome of menopause evidence base. [1] Consensus testosterone guidance supports systemic testosterone only for carefully assessed hypoactive sexual desire disorder, not for dryness, burning, urinary symptoms, or pain from dry tissue. [6] [7]
- Testosterone Therapy for Women After MenopauseThe strongest consensus-backed use of testosterone therapy for women is hypoactive sexual desire disorder after menopause, after a clinician checks relationship, mood, medication, pain, sleep, estrogen, and medical factors. In a 2019 meta-analysis of 36 randomized trials with 8,480 women, testosterone improved sexual-function outcomes, but blood testosterone alone does not diagnose the problem and evidence is not strong enough to use testosterone as a general treatment for fatigue, weight, mood, cognition, or anti-aging. [1]
- Testosterone for Mood After Menopause: What the Evidence ShowsTestosterone should not be presented as a primary treatment for anxiety, depression, brain fog, or low mood after menopause. The strongest consensus statements say the evidence-based indication is hypoactive sexual desire disorder in postmenopausal women after biopsychosocial assessment. A 2019 meta-analysis found 36 randomized trials with 8,480 participants and clearer sexual-function benefits than mood or cognition evidence. [1] [2] A 2025 510-person retrospective pilot reported mood and cognition improvements over 4 months, but it also called for randomized trials before that use is established. [4] A randomized depression trial in 101 women found adjunctive testosterone was not better than placebo for depression, fatigue, or sexual function over 8 weeks. [5]
- Does Testosterone Therapy Cause Hair Loss After Menopause?Prescription testosterone does not have strong evidence that physiologic transdermal dosing causes hair loss in postmenopausal women with hypoactive sexual desire disorder, but hair loss still needs careful triage. A meta-analysis of seven randomized trials with 3,035 participants found more androgenic adverse events, acne, and increased hair growth with testosterone patches, but no significant alopecia difference versus placebo. Rapid hair loss with acne, hirsutism, voice change, or virilization is different and should prompt androgen-excess evaluation. [3]
- Testosterone and Breast Cancer Risk After MenopauseTestosterone therapy for women after menopause should not be sold as breast-cancer prevention or a risk-free optimization plan. Global consensus and International Society for the Study of Women's Sexual Health guidance keep the evidence-based use case focused on hypoactive sexual desire disorder, with physiologic dosing and monitoring. Short-term randomized data and breast-risk reviews are reassuring in some ways, but long-term evidence, high-risk patients, and breast-cancer survivor decisions still need clinician or oncology review. [1]
- Testosterone for Brain Fog After Menopause: What to KnowTestosterone should not be framed as an evidence-based brain-fog treatment after menopause. A 2024 retrospective pilot of 510 women reported mood and cognitive symptom improvement after 4 months, but it was not randomized. In older Australian women, 395-person and 5,511-person analyses did not link testosterone patterns to cognitive performance in a way that supports a treatment indication. [1]
- Testosterone Blood Test for Women After MenopauseTestosterone blood testing in women after menopause is mainly a baseline and monitoring tool, not a stand-alone diagnosis for low desire, fatigue, mood, or weight concerns. International Society for the Study of Women's Sexual Health and global consensus guidance support considering systemic testosterone only for carefully assessed hypoactive sexual desire disorder in postmenopausal women, with levels used to avoid supraphysiologic exposure and monitor safety. Testing belongs in clinician-led context, not as a direct "low T equals treatment" rule. [1]
- Low Testosterone Symptoms in Women After MenopauseFatigue, weight gain, low mood, hair change, and low desire can happen after menopause, but they do not diagnose low testosterone by themselves. The strongest evidence-backed use of systemic testosterone in women is treatment of hypoactive sexual desire disorder after a biopsychosocial assessment. Testosterone levels are used for baseline and monitoring, not as a standalone symptom-score diagnosis. [1]
- DHEA vs Testosterone After MenopauseDehydroepiandrosterone and testosterone are not interchangeable after menopause. A randomized trial of 93 postmenopausal women with low libido found that oral dehydroepiandrosterone 50 mg daily did not significantly improve sexual function over placebo at 26 weeks. More acne and increased hair growth occurred in the dehydroepiandrosterone group. Global testosterone guidance supports systemic testosterone only for carefully diagnosed hypoactive sexual desire disorder in postmenopausal women. Genitourinary syndrome of menopause symptoms such as dryness or painful sex often belong first in a vaginal estrogen, prasterone, ospemifene, or moisturizer pathway. [1]
Common questions
Is testosterone cypionate approved for women?
In the United States, testosterone cypionate labels are written for male hypogonadism and related male indications, not menopause treatment in women. Use in women is an off-label clinical decision that requires careful diagnosis, dosing, and monitoring.
How quickly does testosterone therapy work for women?
For postmenopausal hypoactive sexual desire disorder, International Society for the Study of Women's Sexual Health says average efficacy emerges at about 6 to 8 weeks, many women feel improvement after 4 weeks, and maximal effects in desire and satisfactory sexual events occur around 12 weeks.
Does testosterone treat vaginal dryness?
Testosterone is not the main evidence-based treatment for vaginal dryness. The 2025 AUA/SUFU/AUGS genitourinary syndrome of menopause guideline points dryness, burning, urinary symptoms, and painful sex toward genitourinary syndrome of menopause diagnosis and treatment first. [1]
What is the best-supported reason for testosterone therapy in women?
The global consensus statement says the only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women. The International Society for the Study of Women's Sexual Health guideline provides prescribing standards for systemic testosterone in women with hypoactive sexual desire disorder, including patient selection, dosing, and monitoring.
Can testosterone treat anxiety after menopause?
It should not be framed that way. The 2019 global consensus found the evidence-based testosterone indication for women is hypoactive sexual desire disorder, not anxiety or depression treatment.
Did testosterone patches increase alopecia in trials?
In a meta-analysis of seven randomized controlled trials with 3,035 participants, testosterone patches increased androgenic adverse events, acne, and hair growth, but not alopecia versus placebo.
Does testosterone treat fatigue after menopause?
Current guidance does not support testosterone as a broad fatigue treatment. A 2019 meta-analysis included 36 randomized trials and 8,480 participants, but the clearest benefit was sexual-function improvement in postmenopausal women, not fatigue relief.
Does testosterone prevent breast cancer?
No. Testosterone should not be presented as breast-cancer prevention. The evidence-based prescription use case is hypoactive sexual desire disorder in carefully selected women.